Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a ‘transdifferentiation’ during the clonal evolution

Endi Wang(University of Southern California), Michael Datto(Duke University), Angela Kanaly(Duke University), Charles Blake Hutchinson(Duke University), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Joseph O. Moore(Cancer Institute (WIA)), Siby Sebastian(Duke University), Catherine Rehder(Duke University)

Leukemia & lymphoma/Leukemia and lymphoma

March 23, 2010

10.3109/10428191003699845

Cited by 88

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

|Journal of the National Comprehensive Cancer Network|2017|655

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.

|Journal of Biological Chemistry|1993|375

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362